Welcome to our dedicated page for EXDI news (Ticker: EXDI), a resource for investors and traders seeking the latest updates and insights on EXDI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EXDI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EXDI's position in the market.
Exactus, Inc. (OTCQB:EXDI), soon to be Panacea Life Sciences, Inc. (OTCQB:PLSH), is leveraging the resurgence of air travel at Denver International Airport (DEN), which saw nearly 25 million passengers in the first half of 2021. Panacea is the first company to sell CBD products at DEN, offering over 18 therapeutic products designed to alleviate travel-related discomfort. These products comply with legal standards, containing less than 0.3% THC. Panacea, founded in 2017, has received $20 million in investments and operates a 51,000 sq. ft. certified facility in Colorado.
Exactus, Inc. (OTCQB:EXDI), soon to be Panacea Life Sciences, Inc. (OTCQB:PLSH), is leveraging the resurgence of passenger traffic at Denver International Airport to promote its premium CBD products, with nearly 25 million travelers in the first half of 2021. Panacea has established two kiosk locations in the airport, making it the first company to offer CBD products directly to passengers. The range includes topical CBD items for pain relief, adhering to hemp regulations. Founded in 2017, Panacea has attracted $20 million in investments, continuing to grow in the evolving CBD market.
Exactus, Inc. (OTCQB:EXDI) announces the grand opening of the Panacea Life Sciences Cannabinoid Research Center at Colorado State University on October 19, 2021. Funded by a $1.5 million donation from CEO Leslie Buttorff, the center aims to enhance cannabinoid research, focusing on therapeutics for human and animal health. With a projected market growth rate of 21% CAGR and a forecasted market value of $13.4 billion by 2028, this initiative positions Panacea to lead in cannabinoid research and innovation.
Exactus has announced its acquisition of Panacea Life Sciences, enhancing its position in the hemp-derived CBD market. Panacea, founded by Leslie Buttorff, operates a 51,000 sq ft cGMP certified facility in Colorado and has established a strong product line including gummies, soft gels, and tinctures. The deal involves the issuance of 1,000,000 shares of Series C Convertible Preferred Stock and common stock, with a name change to Panacea Life Sciences Holdings. A 1:28 reverse stock split is also planned, pending regulatory approval.
